Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 天士力医药集团股份有限公司（简称“天士力”）成立于1994年，是华润三九医药股份有限公司旗下的大型国有医药上市公司，主要从事药品研发、生产和销售，2002年8月23日在上海证券交易所挂牌上市（证券代码600535）。作为中药现代化、国际化代表性企业，天士力坚持大生物医药技术定位，以现代中药、生物药、化学药的丰富药品组合，为客户和用户提供一站式、个性化健康服务，同时前瞻布局细胞治疗等产业。2024年实现收入84.98亿元、扣非净利润10.69亿元、纳税9.95亿元，实现稳健发展。荣列国家第八批制造业单项冠军企业、中国医药制造业百强、中国医药创新企业百强、中国医药上市竞争力20强、最具投资价值医药上市公司10强等。 天士力坚持创新中药、先进治疗药物双轮驱动的开放创新体系，以“两棵树”（疾病树+产品树）为指导，形成以现代中药创制全国重点实验室、中药先进制造技术国家地方联合工程实验室等为引领的大生物医药创新研发平台，聚焦心血管及代谢、神经/精神、消化三大疾病领域，开发培育出复方丹参滴丸、养血清脑颗粒（丸）、普佑克、替莫唑胺等各类符合人民需要的高质量药品。荣获4项国家科技进步奖，承担16项国家重大新药创制专项，拥有14个年销售额过亿元产品。 天士力持续推动全产业链绿色智能制造，是国家级智能制造示范工厂，荣获国务院批准设立的第四届“中国工业大奖”。先后5次迭代复方丹参滴丸生产技术，建有世界第一条高速滴丸生产线。首批通过全国两化融合管理体系评定。首创以“质量数字化”为核心的中药智能制造技术体系，主要质控指标均达到制药行业最高水平，实现中药产品批次间质量稳定、均一，经张伯礼、元英进等多位院士领衔的专家团体评定，技术成果达到国际领先水平，荣获2022年度“天津市科技进步特等奖”。 面向未来，天士力积极践行国资央企使命担当，致力于创新驱动，成为中国医药市场的领先企业，不断推动医药健康事业进步，增进人民福祉，服务“健康中国”。
Main Business 复方丹参滴丸、养血清脑颗粒的生产和销售；以复方丹参滴丸为代表的治疗心脑血管疾病类药品和以复方丹参滴丸为基础的丹参系列产品的研究开发。
Legal Representative 蔡金勇
Top Executives
董事长：蔡金勇
副董事长：李克新
董事：原京,喻翔,蔡金勇,王克,王亮,麦毅,周辉
独立董事：段亚林,叶霖,王爱俭,韩秀桃,徐宁
Top 5 Shareholder
Shareholder name Nature Holding Date
华润三九医药股份有限公司流通A股28.00%30/09/2026
天士力生物医药产业集团有限公司流通A股17.21%30/09/2026
国新投资有限公司流通A股5.00%30/09/2026
香港中央结算有限公司流通A股2.60%30/09/2026
刘少鸾流通A股1.14%30/09/2026
Company Secretary 于杰
Solicitors 内蒙古建中律师事务所
Auditors 天健会计师事务所（特殊普通合伙）
Tel No 022-26736999;022-26735302
Fax No 022-26736721
Website www.taslypharma.com
Email stock@taslypharma.com
Company Address
Register: 天津市北辰区普济河东道2号(天士力现代中药城)
Office: 天津市北辰区普济河东道2号（天士力现代中药城）
Listing Date 23/08/2002
Shares Capital
Shares Capital: 1,493,950,005
Total A Share: 1,493,950,005
Listed A Share: 1,493,950,005
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.740
DPS(RMB)* ¥ 0.310
NBV Per Share(RMB)* ¥ 8.303
Market Capitalization(RMB) 20.856B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.